The Tau Consortium is a collaborative research program that is managed and funded by the Rainwater Charitable Foundation in partnership with other funders. Read More
SAN DIEGO, May 4, 2021 /PRNewswire/ -- Origami Therapeutics http://origamitherapeutics.com,a discovery-stage company taking a precision medicine approach to discover diseasemodifyingtreatments for neurodegeneration, announced today it has been selected as one of13...
LABEST 2021 Full Agenda 5.17
Catch up on all of the latest updates from day 2 of the 2021 CHDI Huntington’s disease therapeutics conference #HDTC2021 Read more
Arctoris appoints three experienced industry executives as members of its Advisory Board. Read Article
Official Event Guide- Digital Protein Misfolding Drug Discovery Summit- Hanson Wade
The Awardees for the SVB pitch contest last fall: See Awardees Also learn more with: A Glimpse Into the Mind of the Investor
San Diego, June 2, 2020 – Origami Therapeutics, an early stage biotech company taking a precision medicine approach to find disease-modifying treatments for neurodegenerative diseases caused by protein folding, announced today it has been selected as one of the 60...
Origami Therapeutics named an Innovation Challenge Finalist at upcoming Digital RESI June Conference
San Diego, May 21, 2020 – Origami Therapeutics has been selected as a finalist in the forthcoming Digital RESI June Conference Innovation Challenge. Companies were selected on the basis of innovative technology, strong management team, clear pathway to...
San Diego, May 13, 2020 – Beth Hoffman, CEO and President of Origami Therapeutics Inc has been announced as a panelist and speaker at the upcoming Advancing Women’s Leadership Skills & Opportunities In Pharma & Healthcare, currently scheduled to take place in...